MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 591340 | Name: AG 2000

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AG 2000 is a biochemical.

Chemical Structure

AG 2000
AG 2000
CAS#111712-16-4

Theoretical Analysis

MedKoo Cat#: 591340

Name: AG 2000

CAS#: 111712-16-4

Chemical Formula: C16H13BF7N3OS

Exact Mass: 439.0761

Molecular Weight: 439.16

Elemental Analysis: C, 43.76; H, 2.98; B, 2.46; F, 30.28; N, 9.57; O, 3.64; S, 7.30

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
AG 2000; AG-2000; AG2000;
IUPAC/Chemical Name
5H-Pyrido(1',2':4,5)(1,2,4)thiadiazino(2,3-a)benzimidazol-13-ium, 4-methyl-3-(2,2,2-trifluoroethoxy)-, tetrafluoroborate(1-)
InChi Key
IXVZBEYWFWRNJA-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H13F3N3OS.BF4/c1-10-13-8-24-22-12-5-3-2-4-11(12)20-15(22)21(13)7-6-14(10)23-9-16(17,18)19;2-1(3,4)5/h2-7H,8-9H2,1H3;/q+1;-1
SMILES Code
FC(F)(F)COC1=CC=[N+](C2=NC3=CC=CC=C3N2SC4)C4=C1C.F[B-](F)(F)F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 439.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chang YD, Smith J, Portman D, Kim R, Oberoi-Jassal R, Rajasekhara S, Davis M. Single Institute Experience With Methylphenidate and American Ginseng in Cancer-Related Fatigue. Am J Hosp Palliat Care. 2018 Jan;35(1):144-150. doi: 10.1177/1049909117695733. Epub 2017 Mar 16. PubMed PMID: 28299946. 2: Biswas SK, Yokoyama K, Kamei K, Nishimura K, Miyaji M. Inhibition of hyphal growth of Candida albicans by activated lansoprazole, a novel benzimidazole proton pump inhibitor. Med Mycol. 2001 Jun;39(3):283-5. PubMed PMID: 11446532. 3: Schmarda A, Dinkhauser P, Gschwentner M, Ritter M, Fürst J, Scandella E, Wöll E, Laich A, Rossmann H, Seidler U, Lang F, Paulmichl M. The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channels. Br J Pharmacol. 2000 Feb;129(3):598-604. PubMed PMID: 10711360; PubMed Central PMCID: PMC1571856. 4: Ohta T, Tajima H, Yachie A, Yokoyama K, Elnemr A, Fushida S, Kitagawa H, Kayahara M, Nishimura G, Miwa K, Yamamoto M, Terada T, Ohkuma S. Activated lansoprazole inhibits cancer cell adhesion to extracellular matrix components. Int J Oncol. 1999 Jul;15(1):33-9. PubMed PMID: 10375591. 5: Nagata K, Takagi E, Satoh H, Okamura H, Tamura T. Growth inhibition of Ureaplasma urealyticum by the proton pump inhibitor lansoprazole: direct attribution to inhibition by lansoprazole of urease activity and urea-induced ATP synthesis in U. urealyticum. Antimicrob Agents Chemother. 1995 Oct;39(10):2187-92. PubMed PMID: 8619564; PubMed Central PMCID: PMC162911. 6: Tsuchiya M, Imamura L, Park JB, Kobashi K. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull. 1995 Aug;18(8):1053-6. PubMed PMID: 8535394. 7: Bando T, Kasahara K, Shibata K, Numata Y, Nakatsumi Y, Fujimura M, Matsuda T. Role of sodium pump systems to determine sensitivity to mitomycin C in non-small cell lung cancer cell lines. Anticancer Res. 1995 May-Jun;15(3):769-72. PubMed PMID: 7645956. 8: Nagata K, Takagi E, Tsuda M, Nakazawa T, Satoh H, Nakao M, Okamura H, Tamura T. Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of urease. Antimicrob Agents Chemother. 1995 Feb;39(2):567-70. PubMed PMID: 7726537; PubMed Central PMCID: PMC162584. 9: Nakajima N, Kuwayama H, Iwasaki A, Arakawa Y. Lansoprazole reverses Helicobacter pylori-inhibited gastric epithelial cell growth. J Clin Gastroenterol. 1995;20 Suppl 2:S90-2. PubMed PMID: 7594352. 10: Bando T, Kasahara K, Shibata K, Nakatsumi Y, Fujimura M, Matsuda T. Effect of proton pump inhibitor on cell growth and sensitivity to cis-diamminedichloroplatinum(II) in non-small cell lung cancer cell lines. Anticancer Res. 1994 Nov-Dec;14(6B):2727-30. PubMed PMID: 7872708. 11: Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother. 1993 Apr;37(4):769-74. PubMed PMID: 8494373; PubMed Central PMCID: PMC187756. 12: Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, Tamura T, Imada A. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991 Mar;35(3):490-6. PubMed PMID: 2039199; PubMed Central PMCID: PMC245037. 13: Nagaya H, Satoh H, Maki Y. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther. 1990 Mar;252(3):1289-95. PubMed PMID: 2156997. 14: Nagaya H, Satoh H, Kubo K, Maki Y. Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther. 1989 Feb;248(2):799-805. PubMed PMID: 2537417.